To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis

Multi-Center, Double-Blind, Randomized, Vehicle-controlled, Parallel-Group Study Comparing NYC-0462 Ointment To a Vehicle Control

Status

Withdrawn

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00747032

Enrollment

Registered

2008-09-04

Start date

2010-09-30

Completion date

2011-04-30

Last updated

2012-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Plaque Psoriasis

Brief summary

The aim of this trial is to assess the efficacy of NYC-0462 Ointment in the Treatment of Plaque Psoriasis.Treatment medication will be administered as follows: A thin layer of study product will be applied to the affected skin, excluding the face, once daily, at approximately the same time daily.

Interventions

DRUGNYC 0462 Ointment

To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis

DRUGPlacebo

To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of stable, symptomatic plaque psoriasis * Good health with the exception of psoriasis * % BSA and plaque elevation requirements

Exclusion criteria

* Subjects who are pregnant, nursing or planning a pregnancy within the study participation period. * Subjects who have any systemic or dermatological disorders with the exception of psoriasis

Design outcomes

Primary

Measure	Time frame
Reduction in plaque elevation score	8 weeks

Secondary

Measure	Time frame
Reduction in Investigator´s Global Evaluation, erythema and scaling scores	8 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026